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We describe the epidemiology of invasive Haemophilus 
influenzae disease during 2007–2014 in 12 European 
countries and assess overall H. influenzae disease trends 
by serotype and patient age. Mean annual notification 
rate was 0.6 cases/100,000 population, with an increas-
ing annual trend of 3.3% (95% CI 2.3% to 4.3%). The 
notification rate was highest for patients <1 month of age 
(23.4 cases/100,000 population). Nontypeable H. influen-
zae (NTHi) caused 78% of all cases and showed increas-
ing trends among persons <1 month and >20 years of 
age. Serotype f cases showed an increasing trend among 
persons >60 years of age. Serotype b cases showed de-
creasing trends among persons 1–5 months, 1–4 years, 
and >40 years of age. Sustained success of routine H. 
influenzae serotype b vaccination is evident. Surveillance 
systems must adopt a broad focus for invasive H. influ-
enzae disease. Increasing reports of NTHi, particularly 
among neonates, highlight the potential benefit of a vac-
cine against NTHi.
Haemophilus influenzae, a pleomorphic gram-negative coccobacillus, is a common commensal of the upper 
respiratory tract. It is a human-only pathogen that can cause 
severe invasive disease, including meningitis, pneumonia, 
and septicemia. H. influenzae strains are divided based on 
the presence or absence of a polysaccharide capsule; there 
are 6 encapsulated serotypes (H. influenzae serotypes a 
[Hia], b [Hib], c [Hic], d [Hid], e [Hie], and f [Hif]) and 
nonencapsulated, nontypeable H. influenzae (NTHi) strains. 
Although Hib strains are considered the most pathogenic, 
NTHi accounts for a high proportion of all H. influenzae 
infections because it causes a notable number of noninva-
sive infections, such as otitis media and sinusitis, as well as 
invasive infections (1–4).
Beginning in 1989, countries of the European Union 
and European Economic Area (EU/EEA) began introduc-
ing conjugate Hib vaccination into their routine national 
immunization programs; most countries introduced the 
vaccine before the year 2000. In the prevaccine era, Hib 
was estimated to cause most cases of invasive H. influ-
enzae disease and was a leading cause of bacterial men-
ingitis worldwide, primarily among otherwise healthy 
children <5 years of age (5,6). The introduction of Hib 
vaccine has led to a substantial and sustained reduction in 
infection caused by Hib (7–12) and in pharyngeal Hib car-
riage, resulting in herd protection (8,13,14). The World 
Health Organization recommends the inclusion of Hib 
vaccination in all routine infant immunization programs 
as a 3-dose primary schedule with or without a booster 
dose or as a 2-dose primary schedule with a booster dose 
(15). Since 2010, Hib vaccination has been part of the 
national immunization program in all EU/EEA countries, 
and high coverage has been maintained (16). Following 
the introduction of Hib vaccine, several studies in Eu-
rope and elsewhere reported increasing trends in NTHi, 
Hia, Hie, and Hif infections (3,4,7,17,18), and NTHi is 
now the leading cause of invasive H. influenzae disease 
in EU/EEA countries and other areas worldwide (2–4). 
Most studies do not report evidence of strain replacement 
due to Hib vaccine introduction, although some have sup-
ported this occurrence (7–9,11,17,19–21).
In 1996, the European Union Invasive Bacterial Infec-
tions Surveillance Network began Europe-level surveil-
lance of invasive H. influenzae disease, and since 2007, 
surveillance has been coordinated by the European Centre 
for Disease Prevention and Control (ECDC) (7). We con-
ducted a study to describe the epidemiology of invasive H. 
influenzae disease in EU/EEA countries during 2007–2014 
and to monitor age- and serotype-specific trends during the 
study period.
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Invasive H. influenzae Disease, Europe, 2007–2014
Methods
European Surveillance of Invasive  
H. influenzae Disease
On an annual basis, all 28 EU Member States and 2 EEA 
countries report national surveillance data on invasive H. 
influenzae disease to a central database at ECDC. Most 
of the 30 reporting countries provide data from passive 
surveillance systems, including mandatory reporting, that 
cover their entire national populations (22). All 30 coun-
tries report using the EU case definition for invasive H. in-
fluenzae (23) or a case definition with compatible criteria 
for laboratory confirmation of disease. Invasive H. influen-
zae disease is confirmed by isolation of H. influenzae from 
a normally sterile site; culture is used for confirmation of 
>99% of all reported cases. According to the most recent 
external quality assurance scheme run by the ECDC-fund-
ed IBD-labnet (the invasive bacterial disease laboratory 
surveillance network in Europe), 20 countries also use a 
PCR-based method to confirm species identity. Twenty-
eight countries routinely serotype isolates, most by slide 
agglutination, PCR, or both methods (24).
Data Selection and Preparation
We analyzed data on invasive H. influenzae disease re-
ported to ECDC during 2007–2014. We excluded cases 
not reported as laboratory-confirmed or for patients with 
unreported age or sex. We excluded data from countries 
that 1) had not reported case-based data for all years in the 
study period; 2) had introduced Hib vaccination into their 
national immunization program during the study period; 3) 
had reported >50% of cases as meningitis, Hib, or both, 
which may indicate a surveillance bias toward the reporting 
of these cases; or 4) had not reported serotype data for all 
years and/or had reported serotype data for <50% of cases.
We used surveillance system coverage data and popula-
tion data from Eurostat (http://www.ec.europa.eu/eurostat) 
as denominators for calculating the total and age-specific 
notification rates per 100,000 population. We categorized 
data on age into the following patient age groups; <1, 1–4, 
5–19, 20–39, 40–59, and >60 years of age. We further 
categorized the infant (<1 year of age) age group into <1 
month, 1–5 months, and 6–11 months of age. We estimated 
the denominator in these infant age groups as the total in-
fant population divided by 12 and multiplied by the number 
of months in each age group. Countries that did not report 
data on the age of infants in months were excluded from the 
analysis of infant age groups.
Data Analysis
We described the epidemiology of invasive H. influenzae dis-
ease by year, country, and serotype and by patient age group, 
sex, and clinical presentation. We compared patient age 
distributions by H. influenzae serotype by calculating median 
ages with interquartile ranges and comparing them using the 
Kruskal-Wallis test. The Dunn test was used to perform post 
hoc pairwise multiple comparisons. We used male:female 
notification rate ratios to describe the sex distribution of pa-
tients by age group, serotype, or both. We applied Poisson 
regression models to estimate differences in male and female 
notification rates and male:female notification rate ratios. We 
expressed categorical variables as the number of cases and 
proportion (%) and compared them using the χ2 test.
We assessed overall temporal trends by estimating 
the percentage change in annual notification rates, includ-
ing 95% CIs, by age group, serotype, or both by using 
linear regression analysis of the log of the annual notifi-
cation rate. We used reporting country as a cluster effect 
in the models. We fixed the significance level at p = 0.05 
and used Stata 14 (StataCorp LLC, College Station, TX, 
USA) to analyze data.
Results
We included data from 12 of the 30 EU/EEA countries: 
Belgium, Cyprus, the Czech Republic, Denmark, Finland, 
Ireland, Italy, the Netherlands, Norway, Slovenia, Spain, 
and the United Kingdom. Belgium and Spain had voluntary 
reporting, but the other countries had mandatory reporting. 
Belgium and the Czech Republic described their surveillance 
system as active; all other countries reported having passive 
surveillance systems. Surveillance system population cover-
age was 50% in Spain and 100% in the other 11 countries. 
Together, the surveillance systems in these 12 countries cov-
ered 41% of the total EU/EEA population. The year of Hib 
vaccine introduction in the 12 countries ranged from 1992 
to 2001. With 1 exception, 3-dose vaccination coverage was 
>90% in all countries during the study period; Denmark had 
87%–89% coverage during 2007–2009 (16).
Of the remaining 18 EU/EEA countries, we excluded 
4 for not reporting case-based data for all study years (Bul-
garia, Croatia, Luxembourg, Romania) and 2 for introduc-
ing the vaccine during the study period (Bulgaria, Poland). 
We also excluded 5 countries for reporting >50% of cases 
as meningitis or Hib (Estonia, Greece, Hungary, Latvia, 
Slovakia), and we excluded 8 for not reporting serotype 
data for all years, reporting serotype data for <50% of cas-
es, or both (Austria, France, Germany, Iceland, Lithuania, 
Malta, Portugal, Sweden).
During 2007–2014, the 12 countries included in the 
study reported a total of 10,624 cases of invasive H. in-
fluenzae disease for a mean annual notification rate of 0.6 
cases/100,000 population. The overall notification rate in-
creased 3.3% (95% CI 2.3% to 4.3%) annually during the 
study period (Table 1). By country, the notification rate 
ranged from 1.6 cases/100,000 population (n = 637) in 
Norway to 0.1 case/100,000 population (n = 6) in Cyprus 
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(Figure 1). We observed increasing overall trends in Den-
mark, Italy, the Netherlands, and Spain and insignificant 
trends in all other countries.
Age and Sex of Case-Patients
Of the 10,624 case-patients, 5,907 (56%) were >60 years 
of age, and 888 (8.4%) were <1 year of age (Table 1). 
The notification rate was highest for infants (4.9 cases/ 
100,000 population), followed by persons >60 years of age 
(1.5/100,000). The notification rate among persons >60 
years of age increased 3.8% (95% CI 2.5% to 5.1%) annu-
ally. The age in months was available for 781 (88%) of the 
888 infants; Spain was the only country not to report any 
data on month of age. The notification rate for infants <1 
month of age (23.4 cases/100,000 population) was >7-fold 
higher than that for those 1–5 months of age (3.2/100,000) 
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Table 1. Epidemiologic findings for cases of invasive Haemophilus influenzae disease, by patient age group and year of notification, in 
12 countries in Europe, 2007–2014* 
Age group 
Annual notification rate/100,000 population  
(no. cases) 
Mean annual 
notification rate 
(no. cases) 
M:F 
ratio 
% Change in 
annual notification 
rate (95% CI)† 2007 2008 2009 2010 2011 2012 2013 2014 
<1 y 4.3  
(96) 
4.4 
(101) 
5.4 
(125) 
4.4 
(103) 
5.2 
(120) 
4.7 
(106) 
4.3 
(97) 
6.5 
(140) 
4.9 (888) 1.24 2.8 (2.1 to 8.0) 
 <1 mo‡ 17.5 
(29) 
21.3 
(36) 
24.8 
(43) 
23.2 
(40) 
25.5 
(44) 
20.0 
(34) 
24.3 
(41) 
30.8 
(51) 
23.4 (318) 1.04 5.0 (0.2 to 10.4) 
 1–5 mo‡ 4.5  
(37) 
3.3  
(28) 
3.8 
(33) 
3.0 
(26) 
3.4 
(29) 
2.9 
(25) 
1.9 
(16) 
3.0 
(25) 
3.2 (219) 1.75 7.1  (13.3 to 0.4) 
 6–11 mo‡ 2.3  
(23) 
3.0  
(30) 
3.6 
(37) 
1.8 
(19) 
2.7 
(28) 
3.3 
(34) 
2.8 
(28) 
4.5 
(45) 
3.0 (244) 1.16 6.0 (4.3 to 16.5) 
1–4 y 1.1  
(97) 
0.9  
(80) 
1.0 
(88) 
0.7 
(67) 
0.9 
(80) 
0.7 
(62) 
0.9 
(85) 
1.0 
(93) 
0.9 (652) 1.25 2.01 (8.3 to 4.6) 
5–19 y 0.2  
(58) 
0.2  
(63) 
0.2 
(61) 
0.1 
(45) 
0.2 
(63) 
0.1 
(44) 
0.2 
(57) 
0.2 
(71) 
0.2 (462) 1.29 0.3 (6.3 to 7.3) 
20–39 y 0.2 
(113) 
0.2 
(118) 
0.2 
(111) 
0.2 
(134) 
0.3 
(139) 
0.2 
(114) 
0.2 
(115) 
0.3 
(148) 
0.2 (992) 0.56 2.8 (1.2 to 6.9) 
40–59 y 0.3 
(190) 
0.4 
(204) 
0.4 
(209) 
0.4 
(201) 
0.4 
(255) 
0.4 
(206) 
0.40 
(228) 
0.4 
(230) 
0.4 (1,723) 0.98 1.5 (1.4 to 4.6) 
>60 y 1.3 
(606) 
1.4 
(638) 
1.4 
(675) 
1.5 
(703) 
1.5 
(727) 
1.7 
(848) 
1.7 
(836) 
1.7 
(874) 
1.5 (5,907) 1.28 3.8 (2.5 to 5.1) 
Total§ 0.6 
(1,160) 
0.6 
(1,204) 
0.6 
(1,269) 
0.6 
(1,253) 
0.7 
(1,384) 
0.7 
(1,380) 
0.7 
(1,418) 
0.7 
(1,556) 
0.6 (10,624) 1.05 3.3 (2.3 to 4.3) 
*The study was conducted in Belgium, Cyprus, the Czech Republic, Denmark, Finland, Ireland, Italy, the Netherlands, Norway, Slovenia, Spain and the 
United Kingdom. Data are for a total of 10,624 cases. 
†Bold font indicates statistically significant trends (p = 0.05). 
‡For these age groups, data from only 11 countries are included because Spain did not report data on the age of infant cases by month. 
§Totals do not include data separately shown for infants <1 mo, 1–5 mo, and 6–11 mo of age because those data are included in the <1 y age group.  
 
Figure 1. Notification rate 
for cases of invasive of 
Haemophilus influenzae disease 
in 12 European countries,  
2007–2014. A total of 10,624 
cases were notified.
Invasive H. influenzae Disease, Europe, 2007–2014
and 6–11 months of age (3.0/100,000). The notification 
rate for infants 1–5 months of age decreased 7.1% (95% CI 
−13.3% to −0.4%) annually. The overall male:female noti-
fication rate ratio was 1.05 (95% CI 1.01 to 1.09) (Table 1).
Serotype
H. influenzae serotype was reported for 8,781 (83%) of the 
10,624 patients (Table 2). The age distribution did not dif-
fer between case-patients with serotype reported and those 
with serotype not reported (p = 0.319). Case-patients with-
out a reported serotype were more likely than those with a 
reported serotype to be male (male:female notification rate 
ratio 1.20 vs. 0.97, respectively; p = 0.001).
A total of 6,853 (78%) of the 8,781 cases with a re-
ported serotype were caused by NTHi strains; these strains 
also accounted for most cases in all age groups (Table 2). 
The notification rate for NTHi cases was highest among in-
fants and persons >60 years of age; most cases were in the 
older age group. We observed this same notification pro-
file among Hie (239/8,781 [3%]) and Hif (828/8,781 [9%]) 
cases. Case-patients with Hib infection (811/8,781 [9%]) 
had a lower median age than those with Hie (p<0.001), Hif 
(p<0.001), or NTHi (p<0.001) infection. Hib caused 19% 
(250/1,343) of all cases among children <5 years of age and 
had highest notification rates among infants and children 
1–4 years of age. However, most Hib cases were in per-
sons >40 years of age (Table 2). H. influenzae serotype was 
reported for 86% (673/781) of infants with known month 
of age. NTHi caused most cases in all infant age groups; 
most notably, NTHi caused 97% (263/271) of cases among 
infants <1 month of age (a notification rate of 19.4 cas-
es/100,000 population) (Table 2).
Among 20- to 39-year-old patients, more women than 
men were infected with Hie (male:female notification rate 
ratio 0.09, 95% CI 0.11 to 0.69), Hif (0.55, 95% CI 0.31 to 
0.99), and NTHi (0.44, 95% CI 0.38 to 0.53). Conversely, 
among patients >60 years of age, more men than women were 
infected by Hie (1.45, 95% CI 1.06 to 1.99) and NTHi (1.30, 
95% CI 1.22 to 1.38), and more boys than girls were infected 
by NTHi among children <1 year of age (1.20, 95% CI 1.02 
to 1.42) and 1–4 years of age (1.37, 95% CI 1.11 to 1.69).
The notification rate of NTHi cases increased 7.4% 
(95% CI 5.3% to 9.6%) annually, driven by increasing 
trends in NTHi cases among children <1 year of age and 
persons >20 years of age. The increasing trend in infants 
was driven by a 6.2% (95% CI 2.8% to 9.8%) annual in-
crease in the notification rate among those <1 month of 
age (Table 3). The notification rate of Hib cases decreased 
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Table 2. Mean annual notification rate per 100,000 population and number of cases of invasive Haemophilus influenzae disease by 
serotype and patient age group, in 12 European countries, 2007–2014* 
Variable 
Mean annual notification rate/100,000 population, by serotype (no. cases)† Mean overall 
annual notification 
rate (no. cases) Hia Hib Hic Hid Hie Hif NTHi Non-b 
Total with 
data Unknown  
Age group            
 <1 y 0.05 
(9) 
0.65 
(118) 
0 0 0.06 
(11) 
0.30 
(54) 
3.17 
(578) 
0.005 
(1) 
4.24 
(771) 
0.64 
(117) 
4.90 (888) 
  <1 mo‡ 0.07 
(1) 
0.29 
(4) 
0 0 0 (0) 0.22 
(3) 
19.37 
(263) 
0 19.96 
(271) 
3.46  
(47) 
23.42 (318) 
  1–5 mo‡ 0.01 
(1) 
0.65 
(44) 
0 0 0.06 
(4) 
0.22 
(15) 
1.75 
(119) 
0.01 
(1) 
2.71 
(184) 
0.52  
(35) 
3.23 (219) 
  6–11 mo‡ 0.09 
(7) 
0.74 
(60) 
0 0 0.09 
(7) 
0.33 
(27) 
1.44 
(117) 
0 2.68 
(218) 
0.32  
(26) 
3.00 (244) 
 1–4 y 0.006 
(4) 
0.18 
(132) 
0.001 
(1) 
0.003 
(2) 
0.01 
(8) 
0.07 
(52) 
0.51 
(369) 
0.006 
(4) 
0.79 
(572) 
0.11  
(80) 
0.90 (652) 
 5–19 y <0.001 
(1) 
0.02 
(54) 
<0.001 
(1) 
0 0.003 
(9) 
0.01 
(26) 
0.10 
(277) 
<0.001 
(1) 
0.14 
(369) 
0.03  
(93) 
0.17 (462) 
 20–39 y <0.001 
(1) 
0.02 
(71) 
0 <0.001 
(1) 
0.003 
(12) 
0.01 
(50) 
0.15 
(648) 
<0.001 
(2) 
0.18 
(785) 
0.05 
(207) 
0.22 (992) 
 40–59 y <0.001 
(4) 
0.04 
(189) 
0 <0.001 
(1) 
0.009 
(41) 
0.03 
(153) 
0.21 
(980) 
<0.001 
(1) 
0.30 
(1,369) 
0.08 
(354) 
0.37 (1,723) 
 >60 y 0.001 
(4) 
0.06 
(247) 
0 <0.001 
(6) 
0.04 
(158) 
0.13 
(493) 
1.03 
(4,001) 
<0.001 
(6) 
1.27 
(4,915) 
0.26 
(992) 
1.53 (5,907) 
Overall 
notification rate 
(no. cases)§ 
0.001 
(23) 
0.05 
(811) 
<0.001 
(2) 
<0.001 
(10) 
0.01 
(239) 
0.05 
(828) 
0.42 
(6,853) 
<0.001 
(15) 
0.53 
(8,781) 
0.11 
(1,843) 
0.64 (10,624) 
Median age, y§ 2 43 3 69 66 64 65 32 64 62 63 
IQR, y§ 0–55 3–63 1–5 33–76 53–78 45–75 35–79 2–83 33–78 37–76 34–77 
*The study was conducted in Belgium, Cyprus, the Czech Republic, Denmark, Finland, Ireland, Italy, the Netherlands, Norway, Slovenia, Spain, and the 
United Kingdom. Data are for a total of 10,624 cases. Hia, H. influenzae serotype a; Hib, serotype b; Hic, serotype c; Hid, serotype d; Hie, serotype e; Hif, 
serotype f; NTHi, nontypeable H. influenzae; non-b, cases reported as a non-b H. influenzae strain (It was not known whether these cases were 
encapsulated); IQR, interquartile range. 
†Values are mean annual notification rate/100,000 population (no. cases), except as indicated. 
‡For these age groups, data from only 11 countries are included because Spain did not report data on the age of infant cases by month. 
§Totals do not include data separately shown for infants <1 mo, 1–5 mo, and 6–11 mo of age because those data are included in the <1 y patient age 
group. 
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11.9% (95% CI −16.0% to −7.5%) annually, driven by de-
creasing trends in Hib cases among persons <1 year, 1–4 
years, 40–59 years, and <60 years of age (Figure 2; Table 
3). The decreasing trend in infants was driven by a 25.0% 
(95% CI −32.2% to −17.0%) annual decrease in cases 
among infants 1–5 months of age (Table 3). No significant 
overall trend was observed among Hie or Hif cases or col-
lectively among cases caused by encapsulated serotypes 
Hia–Hif (Figure 2; Table 3). The notification rate of Hie 
cases among children 1–4 years of age decreased 14.2% 
(95% CI −25.0% to −1.7%) annually (Table 3), although 
only 8 cases were reported for this serotype and age group 
during the study period (Table 2). The notification rate of 
Hif cases among persons >60 years of age increased 7.0% 
(95% CI 0.9% to 13.4%) annually (Table 3). Each year dur-
ing 2010–2014, more cases of Hif than Hib were reported 
(Figure 2). Too few cases of Hia, Hic, and Hid were re-
ported to calculate trends for these serotypes (Table 2). The 
notification rate of cases reported with unknown serotype 
decreased 4.8% (95% CI −9.0% to −0.5%) annually (Fig-
ure 2; Table 3).
By country, an 18.5% (95% CI 1.9% to 37.9%) in-
creasing trend in Hib was observed in Italy, although only 
26 cases were reported during the study period, and no 
more than 5 cases were reported in a single year. The noti-
fication rate did not increase significantly for any encapsu-
lated serotype in any other country. The notification rate for 
NTHi cases increased significantly in Belgium, Denmark, 
Ireland, Italy, the Netherlands, Spain, and the United King-
dom (data not shown). In all other countries, the change 
in the NTHi notification rate over the study period was 
not significant.
Clinical Presentation
Clinical presentation was known for 6,722 (63%) of the 
reported 10,624 case-patients. Most had septicemia (4,128 
patients [61%]), bacterial pneumonia (1,207 [18%]), or 
meningitis (596 [9%]). The following clinical presentations 
were also reported: osteomyelitis (75 patients [1%]), men-
ingitis and septicemia (64 [1%]), epiglottitis (52 [1%]), and 
cellulitis (37 [1%]), and other (563 [8%]). Septicemia was 
the most common clinical presentation in all age groups.
Clinical presentation was known for 5,913 (67%) of 
the 8,781 patients with serotyped isolates. For all the dif-
ferent clinical presentations, except epiglottitis, NTHi was 
the most common cause of H. influenzae infection; 78% 
of cases presenting with epiglottitis were caused by Hib. 
Septicemia was reported for most cases caused by Hib 
(51%), Hie (67%), Hif (61%), and NTHi (66%), and it was 
the most common clinical presentation for all age groups 
infected with these serotypes, except infants infected with 
Hie and Hif (60% and 45%, respectively, were reported to 
have meningitis) (Figure 3). Bacterial pneumonia was most 
prominent among older age groups with Hib, Hie, and Hif 
infection, but it was observed across all age groups with 
NTHi infection (Figure 3). Among 212 infants <1 month of 
age with available clinical presentation and serotype data, 
181 (85%) had NTHi infection presenting with septicemia.
Discussion
The sustained low notification rate for Hib and continued 
decreasing infection trend in all age groups (i.e., in those 
targeted and not targeted for vaccination) underscore the 
success of routine Hib vaccination. Among children <5 
years of age with invasive H. influenzae disease, almost 1 
in 5 cases is still caused by Hib, a potentially preventable 
disease. Breakthrough cases of invasive disease follow-
ing Hib vaccination have been reported in immunocom-
promised and healthy children (25,26); however, vaccine 
failures are rare, and additional vaccine doses have are 
an effective way to achieve protective antibody levels in 
such instances (25). Although Hib vaccination has notably 
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Table 3. Percentage change in annual notification rate for cases of invasive Haemophilus influenzae disease, by serotype and patient 
age group, in 12 European countries, 2007–2014* 
Age group 
% Change (95% CI), N = 10,574† 
Hib Hie Hif NTHi Unknown serotype 
<1 y 8.5 (14.5 to 2.1) 4.3 (33.6 to 38.1) 6.2 (23.6 to 15.2) 5.5 (0.6 to 10.8) 4.1 (4.1 to 13.0) 
 <1 mo‡ – – 0.9 (4.3 to 2.6) 6.2 (2.8 to 9.8) 0.3 (19.3 to 23.1) 
 1–5 mo‡ 25.0 (32.2 to 17.0) 2.4 (72.9 to 251.8) 11.7 (8.2 to 36.0) 2.1 (3.3 to 7.7) 7.1 (15.6 to 2.4) 
 6–11 mo‡ 3.5 (18.4 to 31.1) – 4.8 (21.2 to 15.1) 2.7 (9.7 to 16.8) 24.9 (2.9 to 60.7) 
1–4 y 18.4 (32.9 to 0.8) 14.2 (25.0 to 1.7) 10.1 (8.7 to 32.7) 3.8 (3.4 to 11.6) 2.8 (9.3 to 16.5) 
5–19 y 8.3 (26.2 to 14.1) – 0.2 (26.3 to 35.0) 5.3 (4.7 to 16.3) 4.9 (20.3 to 13.5) 
20–39 y 15.0 (29.4 to 2.3) 3.4 (14.8 to 25.5) 1.4 (17.6 to 18.0) 9.7 (5.6 to 13.9) 8.6 (16.2 to 0.3) 
40–59 y 9.0 (14.7 to 3.0) 3.3 (19.8 to 16.7) 7.0 (3.8 to 19.0) 6.8 (2.4 to 11.3) 6.8 (11.0 to 2.3) 
>60 y 12.6 (17.8 to 7.1) 12.7 (2.9 to 30.8) 7.0 (0.9 to 13.4) 7.0 (4.5 to 9.5) 6.0 (12.1 to 0.5) 
Total§ 11.9 (16.0 to 7.5) 6.3 (5.3 to 19.5) 6.4 (1.5 to 14.8) 7.4 (5.3 to 9.6) 4.8 (9.0 to 0.5) 
*The study was conducted in Belgium, Cyprus, the Czech Republic, Denmark, Finland, Ireland, Italy, the Netherlands, Norway, Slovenia, Spain, and the 
United Kingdom. Data are for a total of 10,574 cases. Hib, H. influenzae serotype b; Hie, serotype e; Hif, serotype f; NTHi, nontypeable H. influenzae; – 
no cases reported or no trend could be determined. 
†Bold font indicates statistically significant trends (p = 0.05). 
‡For these age groups, data from only 11 countries are included because Spain did not report data on the age of infant cases by month. 
§Totals do not include data separately shown for infants <1 mo, 1–5 mo, and 6–11 mo of age because those data are included in the <1 y age group. 
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decreased the incidence of invasive Hib disease in all age 
groups, this reduction has been greatest among young chil-
dren (3,10,11,27), and most Hib cases now occur in older 
adults with concurrent conditions (27,28).
In the prevaccine era, NTHi was not a known com-
mon cause of invasive infection (29), but it is now well 
recognized as the leading cause of invasive H. influenzae 
disease (2–4). Higher H. influenzae notification rates for 
infants, particularly neonates, the elderly, and women of 
childbearing age, were described before (30,31) and after 
(32–34) the introduction of routine Hib vaccination. In ad-
dition, several studies showed an increased burden of NTHi 
in groups more susceptible to infection, with high propor-
tions of intensive care admission, high case-fatality rates, 
and frequent sequelae among survivors (2,29,32,35). The 
notification rate of NTHi cases in infants <1 month of age, 
with most cases presenting as septicemia, is particularly 
striking. Studies have shown that most cases in neonates 
are present at the time of birth, and infection may induce 
labor (33), causing premature birth (3,33,36). It is prob-
able that the number of NTHi infections among neonates 
is underestimated (37), although the increasing notification 
rate among infants <1 month of age indicates that reporting 
may be improving. If developed, a vaccine against NTHi 
that could be administered to pregnant women could pro-
vide protection to expectant mothers and neonates (35). 
The genetic diversity of NTHi complicates vaccine devel-
opment, but exploration into potential NTHi vaccine candi-
dates is ongoing (38).
The increasing recognition of NTHi as a key invasive 
pathogen highlights how future surveillance of invasive 
H. influenzae disease must encompass all serotypes and 
strains, age groups, and clinical presentations. EU/EEA 
member states are not required to report all H. influenzae 
strains. Moreover, simply studying NTHi trends may now 
be insufficient for monitoring changes in the epidemiol-
ogy of NTHi strains because they are more genetically di-
verse than encapsulated strains (29,35,37,39). Surveillance 
of NTHi in Europe may benefit from more genetic typing 
studies of circulating strains, with regard to carriage and 
disease, and the standardization of typing methodologies 
(24,36,37).
The notification rate of non-Hib encapsulated sero-
types in Europe remains low and stable. Some studies have 
reported increasing trends in Hia cases after the introduc-
tion of routine Hib vaccination (18,40,41); however, Hia 
remains rare in Europe.
We observed increasing trends in the annual notifica-
tion rate of NTHi cases in persons <1 and >20 years of 
age and of Hif cases in persons >60 years of age. These 
trends may represent an actual increase in the incidence 
of disease, which could result from different factors, such 
as population aging and increased use of immunosuppres-
sive therapy, both of which would increase the number of 
persons at risk for infection by these strains (17,35). De-
spite these increasing trends, we could not assess possible 
strain replacement resulting from the introduction of Hib 
vaccination because we could not compare serotype distri-
butions or incidence between the prevaccination and post-
vaccination periods. Trends also may reflect changes and 
improvements in surveillance that increase case detection, 
such as an increase in awareness among clinicians since 
Hib vaccine introduction, changing blood culture practices, 
and more accurate serotyping techniques. For example, 
since 1993 in the Netherlands, the reporting of NTHi from 
blood isolates has increased, while the reporting of NTHi 
from cerebrospinal fluid isolates has remained stable (42). 
Furthermore, new molecular technologies, such as PCR-
based serotyping, have allowed more accurate differen-
tiation between typeable and nontypeable strains (24,37). 
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Figure 2. Notification rate for 
cases of invasive Haemophilus 
influenzae disease, by serotype 
and year of notification, in 12 
countries in Europe, 2007–2014. 
A total of 8,781 cases were 
notified. Cases were notified 
from Belgium, Cyprus, the Czech 
Republic, Denmark, Finland, 
Ireland, Italy, the Netherlands, 
Norway, Slovenia, Spain, and the 
United Kingdom. *Refers to all 
cases reported as H. influenzae 
serotypes a (Hia), b (Hib), c 
(Hic), d (Hid), e (Hie), and f (Hif).
SYNOPSIS
Such technologies are becoming more widely used across 
the EU/EEA; in 2014, a total of 24 reference laboratories 
performed PCR-based serotyping, compared with 19 labo-
ratories in 2012 (24).
Limitations of our study were the need to combine 
and compare data from different countries that had pos-
sible differences in surveillance sensitivity and methodol-
ogy and the predisposition for underreporting in routine 
passive surveillance systems (43). The notification rate 
of invasive H. influenzae disease in the United States 
in 2014, detected through Active Bacterial Core sur-
veillance, was >2 times that of the 12 countries in this 
study (44). Nevertheless, for the entire study period, all 
included countries used comparable case definitions and 
reported consistently high quality data for all age groups, 
serotypes, and clinical presentations, thus indicating no 
potential surveillance bias. Together, these 12 countries 
covered 41% of the EU/EEA population, higher than the 
population coverage in similar large studies (3,7), and 
trends observed in each country were consistent with the 
pooled results for Europe. The surveillance of invasive H. 
influenzae disease on the Europe level is longstanding (7) 
and allows the pooling of data to increase the precision of 
estimates for what is now a rare disease in the EU/EEA. 
National reference laboratories in all countries participate 
in the external quality assurance schemes and training 
run by IBD-labnet (24). Unfortunately, we could not as-
sess specific risk factors, such as concurrent conditions, 
or sequelae among surviving case-patients because such 
data are not collected at ECDC. We also could not assess 
potential vaccine failures because the date of last vaccina-
tion was not collected for patients, and the completeness 
of data regarding the vaccination status of patients with 
Hib infection was low. In addition, data on fatal outcome 
were not included because completeness of the data was 
low. These limitations, along with the fact that data from 
only 12 of 30 countries were included, underscore the 
potential for improving the scope and quality of data re-
ported to ECDC and increasing the value of surveillance 
on the Europe level.
In conclusion, the sustained success of routine Hib 
vaccination is evident, however the epidemiology of in-
vasive H. influenzae disease must continue to be carefully 
monitored through surveillance systems with a broad fo-
cus. In addition, the continually increasing reporting of 
invasive disease caused by NTHi, particularly among neo-
nates, highlights the potential benefit of the development of 
a vaccine against NTHi.
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Figure 3. Percentage of cases, by 
patient age group, in 12 countries 
in Europe with various clinical 
presentations of Haemophilus 
influenzae disease caused by 
serotypes b (A), e (B), and f (C) 
and by nontypeable H. influenzae 
(D), 2007–2014. Cases (N = 5,879) 
were in Belgium, Cyprus, the 
Czech Republic, Denmark, Finland, 
Ireland, Italy, the Netherlands, 
Norway, Slovenia, Spain, and the 
United Kingdom. *Refers to cases 
reported as other, cellulitis, septic 
arthritis, or osteomyelitis.
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